LATTICE – Safety & efficacy of BMS-986165 in participants with moderate-to-severe Crohn’s Disease
Study code
NBR52
Lead researcher
Dr Tim Raine
Study type
Participant re-contact
Institution or company
University of Cambridge/BMS
Researcher type
Commerical
Speciality area
Gastroenterology
Recruitment Site
{
"address": {
"latlng": "52.174685, 0.141910"
},
"mapconfig": {
"apikey": "AIzaSyCeuuJiDEX-dHyrzK57R066-Z2rpLJs038",
"zoom": 15,
"maptype": "Roadmap",
"mapcenter": "52.170315105960235, 0.14797670472074476"
}
}
Summary
This is an investigational study, also known as LATTICE, of the experimental medication BMS-986165 in patients with moderate to severe Crohn's Disease, a chronic bowel disease that causes severe inflammation of the digestive tract. MS-986165 is an investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, which has been studied in a phase 2 trial of patients with moderate to severe plaque psoriasis (https://news.bms.com/pressrelease/bristolmyers/bristol-myers-squibbs-novel-oral-selective-tyk2-inhibitor-delivered-signi). The study is a phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of BMS986165.